Business Description
Transgene SA
ISIN : FR0005175080
Total Employee Number:
155Compare
Compare
Traded in other countries / regions
TNG.FranceTGNA.Germany0OCQ.UKTRGNF.USA IPO Date
2008-05-19Description
Transgene SA is a biotechnology company that designs and develops virus based immunotherapy products focused on the development of individualized therapeutic vaccines against cancers. The flagship program, TG4050, is an individualized therapeutic vaccine based on the myvac platform. The company also has other viral vector-based programs, including BT-001, an oncolytic virus based on the Invir.IO viral backbone, which is in clinical development. In addition, it conducts discovery and preclinical work, aimed at developing novel immunotherapies.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.88 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-Equity | 0.24 | |||||
Debt-to-EBITDA | -0.83 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 6.66 | |||||
Beneish M-Score | -1.35 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -55.9 | |||||
3-Year EBITDA Growth Rate | 7.6 | |||||
3-Year EPS without NRI Growth Rate | 7.6 | |||||
3-Year FCF Growth Rate | -6.2 | |||||
3-Year Book Growth Rate | 5.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 43.66 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 88.45 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 39.38 | |||||
9-Day RSI | 27.83 | |||||
14-Day RSI | 29.19 | |||||
3-1 Month Momentum % | 4.88 | |||||
6-1 Month Momentum % | -15.53 | |||||
12-1 Month Momentum % | 1.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.62 | |||||
Quick Ratio | 9.62 | |||||
Cash Ratio | 9.14 | |||||
Days Sales Outstanding | 1431.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -39.8 | |||||
Shareholder Yield % | -63.72 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -6938.37 | |||||
Net Margin % | -7657.96 | |||||
EBITDA Margin % | -7120.2 | |||||
FCF Margin % | -7732.24 | |||||
OCF Margin % | -7560.41 | |||||
ROE % | -84.43 | |||||
ROA % | -50.71 | |||||
ROIC % | -107.84 | |||||
3-Year ROIIC % | 77.01 | |||||
ROC (Joel Greenblatt) % | -260.87 | |||||
ROCE % | -69.82 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 20.64 | |||||
PS Ratio | 188.75 | |||||
PB Ratio | 1.7 | |||||
Price-to-Tangible-Book | 1.71 | |||||
EV-to-EBIT | -2.71 | |||||
EV-to-EBITDA | -2.82 | |||||
EV-to-Revenue | 200.46 | |||||
EV-to-Forward-Revenue | 30.24 | |||||
EV-to-FCF | -2.59 | |||||
Price-to-GF-Value | 1.41 | |||||
Price-to-Median-PS-Value | 3.5 | |||||
| Price-to-Net-Current-Asset-Value | 2.04 | |||||
| Price-to-Net-Cash | 2.16 | |||||
Earnings Yield (Greenblatt) % | -36.9 | |||||
FCF Yield % | -18.03 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Transgene SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.49 | ||
| EPS (TTM) (€) | -0.26 | ||
| Beta | 1.5924 | ||
| 3-Year Sharpe Ratio | -0.71 | ||
| 3-Year Sortino Ratio | -0.92 | ||
| Volatility % | 45.62 | ||
| 14-Day RSI | 29.19 | ||
| 14-Day ATR (€) | 0.005321 | ||
| 20-Day SMA (€) | 0.7524 | ||
| 12-1 Month Momentum % | 1.75 | ||
| 52-Week Range (€) | 0.724 - 1.5 | ||
| Shares Outstanding (Mil) | 278.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Transgene SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Transgene SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Transgene SA Frequently Asked Questions
What is Transgene SA(LTS:0OCQ)'s stock price today?
The current price of LTS:0OCQ is €0.73. The 52 week high of LTS:0OCQ is €1.50 and 52 week low is €0.72.
When is next earnings date of Transgene SA(LTS:0OCQ)?
The next earnings date of Transgene SA(LTS:0OCQ) is .
Does Transgene SA(LTS:0OCQ) pay dividends? If so, how much?
Transgene SA(LTS:0OCQ) does not pay dividend.
Press Release
Articles on Transgene SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers